

OneSource announces strong financial results in its first quarter post-listing; Q3FY25 revenues at ₹3,926 million with an EBITDA of ₹1,432 million, demonstrating a 36.5% EBITDA margin

Q3FY25 Performance Highlights

- Revenues of ₹3,926 million grew 18% QoQ.
- EBITDA grew 85% QoQ to ₹1,432 million.
- EBITDA margin of 36.5% grew by 1,334 basis points QoQ.
- Q3 FY25 normalized PAT was ₹898 million, resulting in an EPS of ₹7.8 for the quarter.
- Reported PAT was impacted by one-time OneSource setup and transaction costs.

Bangalore, India, January 29, 2025 - OneSource Specialty Pharma Limited (BSE:544292, NSE: ONESOURCE) today announced its consolidated financial results for the quarter (Q3FY25) ended December 31, 2024.

Financial Highlights (In ₹ million)

| Particulars | Q3FY25 | Q2FY25 | QoQ | 9 months FY25 |
|----------------|------------|--------|-----------|---------------|
| Revenues | 3,926 | 3,340 | 18 % | 10,189 |
| Gross Margin | 3,023 | 2,240 | 35 % | 7,436 |
| Gross Margin % | 77% | 67% | 995 bps | 73% |
| EBITDA | 1,432 | 773 | 85% | 2,848 |
| EBITDA % | 36.5% | 23% | 1,334 bps | 28% |
| Normalised PAT | 898 | | | |
| Normalised EPS | ₹7.8/share | | | |

Normalised PAT = Excluding exceptional items, interest on discontinued debt & Scheme amortization

Mr. Neeraj Sharma, CEO, OneSource Specialty Pharma Limited speaking on the performance said, *“We're off to a promising start as an independent platform. Our strong Q3 results and impressive new business wins across various modalities demonstrate we're on the path to continued growth and profitability while achieving the targeted FY25 outcomes. We're committed to providing significant value and establishing ourselves as the leading Indian CDMO on a global stage.”*

Detailed investor communication on the performance of the Company is attached.

About OneSource Specialty Pharma Limited

OneSource Specialty Pharma Limited (BSE:544292, NSE: ONESOURCE), formerly known as Stelis Biopharma Limited, is India's first specialty pharma pure-play CDMO business. Our comprehensive solutions span across platforms and therapeutic modalities, including, Drug-device Combinations, Biologics, Sterile Injectables, and Oral Technologies. Committed to innovation and excellence, we support our global partners in delivering life-saving products efficiently. OneSource Specialty Pharma operates five state-of-the-art facilities, all approved by major regulatory bodies, including the USFDA and EU authorities. Along with a team of over 1,200 professionals, we specialize in diverse dosage formats and advanced biologics platforms. For more details please visit the company website at www.onesourcecdmo.com

For further information, please contact:

| | |
|--|---|
| <p><u>Institutional Investors</u> Anurag Bhagania CFO Email: investor-relations@onesourcecdmo.com</p> | <p><u>Corporate Communication</u> Pallavi Panchmatia: +91 8951939181 Abhilash Mukherjee: +91 89044 28907 Email: corpcomm@onesourcecdmo.com</p> <p><u>PR Consultancy</u> Adfactors PR Janhavi Bellare: +91 93228 54508 Email: Janhavi.bellare@adfactorspr.com Syed Talal: +91 99876 19679 Email: syed.talal@adfactorspr.com</p> |
|--|---|